HighTower Advisors
GPCR icon

HighTower Advisors’s Structure Therapeutics GPCR Stock Holding History

HighTower Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
10,029
+409
+4% +$18.1K ﹤0.01% 2679
2026
Q1 		$464K Buy
9,620
+300
+3% +$20.5K ﹤0.01% 2791
2025
Q4 		$648K Buy
9,320
+320
+4% +$13.1K ﹤0.01% 2435
2025
Q3 		$252K Buy
+9,000
New +$179K ﹤0.01% 3186

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighTower Advisors's GPCR Position: Q2 2026 in Review

HighTower Advisors increased its Structure Therapeutics (GPCR) stake by 4.3% in Q2 2026, buying an estimated $18.1K and bringing the position to 10,029 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

HighTower Advisors first reported a position in GPCR in Q3 2025 and has held it in 4 quarters since. The position peaked at $648K in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • HighTower Advisors held 10,029 shares of Structure Therapeutics worth $538K as of Q2 2026.
  • HighTower Advisors bought 409 Structure Therapeutics shares in Q2 2026, an estimated $18.1K.
  • Structure Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2679 holding.
  • HighTower Advisors first reported a position in Structure Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • HighTower Advisors's Structure Therapeutics position peaked at $648K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.